PNEC Calculated from Chronic Data. 5-fluorouracil Vestel et al abiraterone acetate Vestel et al. 2016

Similar documents
Ontario Drug Benefit Formulary/Comparative Drug Index

MHPILMCD RXMCDP OXYCODON ACETAMINOPHEN /11/2018 New Add Newly Added NDC

HPLC&LC-MS/MS 用試薬キット対応一覧表 - ( 株 ) エスエイエス ( )

HPMMCR MHPMICOMP MHPILCOMPB

Highlighted medications are NOT covered by Wal-Mart's Plan!!

GCN NDC Label Name MAC Price Effective Date Prev Price Reason DICYCLOMINE 20 MG/2 ML VIAL /23/2018 New Add Newly Added NDC

PRINCE EDWARD ISLAND DRUG PROGRAMS INTERCHANGEABLE/MAXIMUM REIMBURSABLE PRICE LIST EFFECTIVE DATE APRIL 22, 2019

Highlighted medications are NOT covered by Wal-Mart's Plan!!

PRSMEDDPRSMCC1 PRSMEDDPRSMPACE PRSMEDCPRSMPACE

Canadian Pharmaceutical Corporation Products

OXYCODON ACETAMINOPHEN /11/2018 New Add Newly Added NDC

SHORT DATED OFFERING SHEET (BY PRODUCT NAME) AS OF

SUPPORTING INFORMATION. Prediction of Synthetic Accessibility Based on Commercially Available Compound Databases

Value-Priced Medication List

Value-Priced Medication List

Current Effective Date

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Value Formulary July 1, 2018 Updates. Formulary. Alternatives

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary July 1, 2018 Updates Formulary. Alternatives

UPDATE AY Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective September 27, 2013 SUMMARY OF CHANGES

Value-Priced Medication List

UPDATE AV Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective June 27, 2013 SUMMARY OF CHANGES

UPDATE AQ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective February 28, 2013 SUMMARY OF CHANGES

PUBLIC PROCUREMENT AUTHORITY

Compendium of Notified Ceiling Prices NLEM 2011

PUBLIC PROCUREMENT AUTHORITY UPDATE OF PRICES FOR COMMON USER ITEMS

PUBLIC PROCUREMENT AUTHORITY

Product Selection Committee / Comité de sélection des produits

Prescription Pharmaceuticals DETAIL & PRICES AVAILABLE UPON REQUEST. All Available Products, Details & Prices Available Upon Enquiry GENERICS

UPDATE AX Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 29, 2013 SUMMARY OF CHANGES

UPDATE AD Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective January 19, 2012 SUMMARY OF CHANGES

UPDATE AZ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 31, 2013 SUMMARY OF CHANGES

UPDATE AH Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective May 29, 2012 SUMMARY OF CHANGES

UPDATE AL Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective 28 September, 2012 SUMMARY OF CHANGES

UPDATE AB Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 25, 2011 SUMMARY OF CHANGES

Item Description Packaging Price

The electronic Medicines Compendium ( emc )

DESCRIPTION FORMULA UNIT PACK

PRINCE EDWARD ISLAND DRUG PROGRAMS INTERCHANGEABLE/MAXIMUM ALLOWABLE COST LIST. EFFECTIVE DATE January 18, 2010

Excellus BlueCross BlueShield Medicare Employer Group Plans

Apotex Products Canada

Medicare Blue Choice Optimum (HMO-POS) Medicare Blue Choice Select (HMO-POS) Medicare Blue Choice Value (HMO) Medicare Blue Choice Value Plus (HMO)

UPDATE AC Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective December 15, 2011 SUMMARY OF CHANGES

AFFINITY MEDICARE. Passport Essentials (HMO) Passport Essentials NYC (HMO) Solutions (HMO-SNP) Ultimate (HMO-SNP)

WHODrug B3- and C3-formats

U.S. PHARMACEUTICAL APPLICATION

PUBLIC PROCUREMENT AUTHORITY

Simultaneous Determination and Validation of Olmesartan Medoximil and Metoprolol Tartarate by Analytical Technique RP-HPLC

Magellan Rx Medicare Basic (PDP) 2019 Formulary

Discovery Health PBR formulary and benchmark pricing

2006 IEHK BASIC UNIT ( 1 complete IEHK = 10 Basic unit)

ALL PAGES OF THE ORDER FORM HAVE TO BE FAXED SPECIAL NOTICES

The innovative Swiss pharmaceutical company. Olfen TM. Flexibility in treatment of pain

This time I am going to present a form of fitting out a simple compound microscope as a polarizing microscope with extremely good results.

Put InfinityLab Poroshell 120 Chiral innovation to work for your challenging separations. Application Compendium

Liaison Information Report (LIR) Healthcare & Public Heath Sector Pharmaceutical Industry

PEI PROVINCIAL INTERCHANGEABLE DRUG LIST

2017 Formulary Annual Notice of Change

VertiSep TM UPS. HPLC Columns. VertiSep TM UPS HPLC Columns

Problems in Designing Huge Datawarehouses and Datamarts

YES = formulary NO = non-formulary NO BENEFIT = excluded

BESTMED MEDICINE FORMULARY FOR CDL-CHRONIC (CHRONIC DISEASE LIST) CONDITIONS

EnvisionRxPlus (PDP) 2017 Comprehensive Formulary. (List of Covered Drugs)

Borders Formulary Committee. Annual report 2012/13

National Cyber Security Strategy (NCS) Toolkit

UPDATE 12 Ontario Drug Benefit Formulary/Comparative Drug Index No. 40 Effective MAY 16, 2008 SUMMARY OF CHANGES

MD1-91 is presented as 96 x 1 ml conditions / MD1-92-FX is presented as 96 x 100 µl conditions.

Reagents also compatible in Hach

columns IonSwift MAX-100 Anion-Exchange Column

COMPASS LABORATORY SERVICES COLLECTION PROCEDURES AND FAQS

YES = formulary NO = non-formulary NO BENEFT = excluded

Risk Management. Continuity Management

English Scale A-20 persons MSN 1768

The role of Standardization in support of harmonization

2019 Drug Formulary. Effective April For federal employees and retirees on the Federal Employees Health Benefits Program

WELFORD CHART NOTES NEWSLETTER

2019 Drug Formulary. Effective March For federal employees and retirees on the Federal Employees Health Benefits Program

SIRA Piemonte: PF Cooperation Tools

COVERAGE DETERMINATION REQUEST FORM

HOLIDAY HOME WORK CLASS X ENGLISH

Chapter 1. Chapter 2. Chapter 3

Preemptive PREventivE Methodology and Tools to protect utilities

UPDATE Q Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective April 23, 2010 SUMMARY OF CHANGES

Green Chemistry and Commerce Council Roundtable

Strengthening International Systems of Conformity Assessment

Notice inviting e-tender. Tender Ref. No. - RDPL/ MAT/ /RM-27 Dated- 25/01/2014

Environmental and Security Initiative (ENVSEC) Information Day NATO Science for Peace and Security Programme 4 February, 2010, Istanbul/Turkey

Global Anti-counterfeit Market Size, Status and Forecast 2025

DEVELOPING MEASURES AND ANALYTIC APPROACHES

Mohamed I Walash, Fathallah F Belal, Nahed M El-Enany * and Mahmoud H El-Maghrabey. Abstract

Release Document for ChartMaker 2016 (fv6.1.4) Last Updated: 04/19/2016

Application Security Training Program

Outputs of EUnetHTA joint work applied in HTA Agencies

Optimizing System Dispersion on the Agilent 1290 Infinity II LC

2018 Drug Formulary. Effective October For large employer groups with a 5-tier in-network pharmacy benefit. PEBB SoundChoice.

2016 Formulary Annual Notice of Change. Medicare Advantage Plans (MAPD)

RESILIENT UTILITY COALITION OF SOUTH FLORIDA

How validation and verification work in JCM. 22 January 2014 Kenta Usui Climate and Energy Area, IGES

Collective action and the B20 agenda

Stakeholders Day 30 January 2018

User Guide to the OECD Product Release and Exposure Data Warehouse

Transcription:

These predicted no-effect concentrations, PNECs, are provided to facilitate environmental risk assessment of pharmaceuticals in surface water downstream of the mixing zone (i.e., not at the point of discharge or entry into the environment) by interested stakeholders. The chronic PNECs were derived from guideline studies (e.g., OECD, USFDA, USEPA) and the application of an appropriate assessment factor. This is the same data required to register a new pharmaceutical in Europe. For some pharmaceuticals, only acute data are available and were used with the appropriate assessment factor. The references are to peer reviewed publications, and also to unpublished internal company documents for a limited number of compounds. Compound Name 5-fluorouracil -0.89 0.2 Vestel et al. 2016 abiraterone acetate 5.12 0.0013 Vestel et al. 2016 acyclovir -1.2 200 Vestel et al. 2016 AIC (5-amino-1H-imidazole-4- carboxamide) -1 82.4 Vestel et al. 2016 alfuzosin 1.51 200 Vestel et al. 2016 alvimopan 0.52 3.4 Vestel et al. 2016 anastrozole 1.58 1 Vestel et al. 2016 anidulafungin 5.09 5 Vestel et al. 2016 aprepitant 4.75 1.8 Vestel et al. 2016 aripiprazole 2.95 0.261 Vestel et al. 2016 articaine 92 Johnson & Johnson atazanavir 3.3 410 Vestel et al. 2016 atenolol 0.015 148 Vestel et al. 2016 atorvastatin 1.42 14 Vestel et al. 2016 azithromycin 0.48 0.019 Vestel et al. 2016 bambuterol HCl 71 bedaquiline 2.93 0.077 Vestel et al. 2016 bezafibrate 4.25 1000 Vestel et al. 2016 Page 1 of 6

bicalutamide 2.54 1 Vestel et al. 2016 budesonide 3.3 8.6 bupivacaine HCl monohydrate 39 bupropion 1.54 10 Vestel et al. 2016 canagliflozine 3.42 56 Vestel et al. 2016 candesartan 1.63 100 Vestel et al. 2016 capecitabine 4.5 280 Vestel et al. 2016 carisbamate 1.2 96 Vestel et al. 2016 carvedilol 2.73 5 Vestel et al. 2016 casopitant 4.13 63.9 Vestel et al. 2016 ceftobiprole -2.2 0.022 Vestel et al. 2016 celecoxib 3.18 1.1 Vestel et al. 2016 cetirizine 100 Johnson & Johnson chlorthalidone 80 Snape 2015 cimetidine 0.199 176 Vestel et al. 2016 cinacalcet hydrochloride 4.79 0.25 Vestel et al. 2016 cisapride 1000 Johnson & Johnson clomethiazole edisilate 62 clopidogrel bisulfate 3.96 31 Vestel et al. 2016 codeine 216 or 500 Vestel et al. 2016 or J&J dalcetrapib 6 0.0074 Vestel et al. 2016 Page 2 of 6

dapagliflozin 100 Snape 2015 dapoxetine HCl 5.09 0.73 Vestel et al. 2016 darunavir 2.47 940 Vestel et al. 2016 diazepam 2.99 27.3 Vestel et al. 2016 diclofenac 4.51 32 Vestel et al. 2016 diphenhydramine 0.1 Johnson & Johnson domperidone 3.96 12 Johnson & Johnson doripenem -2.7 0.11 Vestel et al. 2016 doxorubicin 1.8 Johnson & Johnson dronedarone 4.63 0.4 Vestel et al. 2016 efavirenz 5.4 2.6 Vestel et al. 2016 entecavir -0.82 32 Vestel et al. 2016 eplerenone 1.02 20 Vestel et al. 2016 eplivanserin 2.29 11.9 Vestel et al. 2016 erlotinib HCl 3.57 52 Vestel et al. 2016 esomeprazole Na 2.24 100 Vestel et al. 2016 estradiol 4.01 0.002 Caldwell et a. 2012 estriol 0.06 Caldwell et al. 2012 estrone 0.006 Caldwell et al. 2012 ethinylestradiol 3.67 0.0001 Caldwell et al. 2012 etoricoxib 2.3 75 Vestel et al. 2016 Page 3 of 6

ezetimibe 4.36 5.1 Vestel et al. 2016 felodipine 5 0.005 formoterol fumarate 0.41 94 fosamprenavir Ca 1 2000 Vestel et al. 2016 fulvestrant 7.67 0.0001 Vestel et al. 2016 gefitinib 4.15 3.2 Vestel et al. 2016 haloperidol 4.3 0.4 Johnson & Johnson hydrochlorothiazide 0.04 200 Vestel et al. 2016 ibuprofen 1 Johnson & Johnson ibrutinib 4 2 Vestel et al. 2016 irbesartan 704 Vestel et al. 2016 ketoconazole 3.78 0.05 Vestel et al. 2016 lamotrigine 1.4 150 Vestel et al. 2016 laropiprant 2.4 950 Vestel et al. 2016 lidocaine hydrochloride 1.6 110 linezolid 0.55 20 Vestel et al. 2016 lisinopril dihydrate -1.01 100 mepivacaine HCl 59 meropenem 1.5 Snape 2015 metformin -2 1030 Vestel et al. 2016 methylphenidate HCl -3.06 77 Vestel et al. 2016 Page 4 of 6

metoprolol succinate -0.9 7.3 miconazole nitrate 3.4 0.2 Vestel et al. 2016 montelukast 4.3 7.3 Vestel et al. 2016 naproxen 4.2 omeprazole 2.24 83 Snape 2015 paliperidone 2.39 250 Vestel et al. 2016 pazopanib 3.33 15 Vestel et al. 2016 pregabalin -1.9 100 Vestel et al. 2016 prilocaine HCl 1.4 61 propofol 3.9 0.37 Vestel et al. 2016 propranolol HCl 0.72 0.02 Vestel et al. 2016 quetiapine fumarate 10 (8) Vestel et al. 2016 (Murray-Smith) raltegravir 0.328 860 Vestel et al. 2016 ramipril 100 ribavirin -2.29 0.097 Vestel et al. 2016 ridaforolimus 4.68 0.0031 Vestel et al. 2016 rilpivirine 4.66 2 Vestel et al. 2016 rimonabant 5.61 1.6 Vestel et al. 2016 rivaroxaban 8.6 Vestel et al. 2016 ropivacaine HCl 34 rosuvastatin calcium 0.28 1.8 Vestel et al. 2016 Page 5 of 6

saxagliptin 0.114 190 Vestel et al. 2016 simeprevir 0.1 Vestel et al. 2016 sitagliptin -0.03 390 Vestel et al. 2016 sulfamethoxazole 0.89 0.2 Vestel et al. 2016 sutent 2.4 2.7 Vestel et al. 2016 tamoxifen citrate 3.68 0.49 Vestel et al. 2016 tapentadol 2.87 53 Vestel et al. 2016 taranabant 5.49 2.1 Vestel et al. 2016 telcagepant 3.65 350 Vestel et al. 2016 terbutaline sulphate -1.8 240 ticagrelor 4.02 53 Vestel et al. 2016 topiramate 3.74 93 Vestel et al. 2016 tramadol 73 Vestel et al. 2016 trimethoprim 0.91 120 Vestel et al. 2016 vicriviroc maleate 0.04 270 Vestel et al. 2016 vorinostat 1.42 1.1 Vestel et al. 2016 zafirlukast 2.3 12.8 Vestel et al. 2016 zolmitriptan 100 Vestel et al. 2016 Page 6 of 6